Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Sensitivity and Tests for Evaluation of Plantar Fasciopathy (STEP)

28 avril 2026 mis à jour par: Istituto Ortopedico Rizzoli

Plantar fasciopathy (PF), one of the leading causes of foot pain, affects up to one in ten individuals in their lifetime. Characterized by pain and structural alterations at the proximal insertion of the plantar fascia on the calcaneus, the term "PF" has replaced "plantar fasciitis," as degenerative tissue changes predominate over inflammatory processes.

The pathogenesis of PF remains incompletely understood but appears to involve the gastrocnemius muscle, which is part of an integrated biomechanical unit including the calcaneus and the plantar fascia. Diagnosis is primarily based on clinical history and physical examination, while imaging modalities such as ultrasound and magnetic resonance imaging assist in excluding differential diagnoses. A simple clinical test to distinguish PF from other causes of heel pain, such as plantar fat pad syndrome or Baxter's nerve entrapment, could improve diagnostic efficiency.

Given the biomechanical relationship between the Achilles tendon and the plantar fascia, and their shared association with gastrocnemius tightness, a clinical test adapted from Achilles tendon assessment may be useful for diagnosing PF. In 2003, the Royal London Hospital proposed a diagnostic approach for Achilles tendinopathy based on pain reduction during active ankle dorsiflexion, which reduces tension in the tendon. The same concept could be applied, with appropriate modifications, to PF.

The present study aims to evaluate the sensitivity, specificity, reproducibility, and predictive value of localized tenderness at the medial calcaneal tuberosity and of a modified version of the Royal London Hospital Test in patients with PF. Secondarily, it will assess the reproducibility and prevalence of the Silfverskiöld test, supporting the concept of a biomechanical unit involving the triceps surae, calcaneus, and plantar fascia.

Aim of this study is to evaluate the sensitivity, specificity, reproducibility, and predictive value of tenderness at the medial calcaneal tuberosity and of a modified version of the Royal London Hospital Test in patients presenting with clinical signs of PF. The modified version of the Royal London Hospital Test for PF has not yet been formally validated in the literature. However, the study was designed following the methodology adopted by Prof. Maffulli for the validation of the original test. Therefore, this is an exploratory study aimed at collecting preliminary data on this new diagnostic test. The secondary objectives of this study is to evaluate the reproducibility and prevalence of the Silfverskiöld test in the study population.

Aperçu de l'étude

Description détaillée

Plantar fasciopathy (PF) is one of the most common causes of foot pain, affecting a substantial proportion of the population במהלך their lifetime. It is characterized by pain and structural alterations at the proximal insertion of the plantar fascia on the calcaneus. The term "plantar fasciopathy" is preferred over "plantar fasciitis," as degenerative tissue changes and thickening are considered to predominate over inflammatory processes.

The pathogenesis of PF remains incompletely understood but is thought to involve the gastrocnemius muscle within an integrated biomechanical unit that includes the triceps surae complex, the calcaneus, and the plantar fascia. PF has a relevant clinical and socioeconomic impact, affecting quality of life and functional capacity, particularly in individuals exposed to prolonged standing or weight-bearing activities. Although most patients respond to conservative treatment, a subset develops persistent or refractory symptoms.

Diagnosis is primarily clinical, based on patient history and physical examination. Imaging modalities such as ultrasound and magnetic resonance imaging are mainly used to exclude alternative causes of heel pain. However, the relationship between imaging findings and symptom severity remains inconsistent, and there is currently no simple, standardized clinical test with established diagnostic accuracy for PF. The availability of a reliable bedside test capable of distinguishing PF from other causes of heel pain would improve diagnostic efficiency and clinical decision-making.

Given the anatomical and biomechanical relationship between the Achilles tendon and the plantar fascia, and their shared association with gastrocnemius tightness, adapting a clinical test originally developed for Achilles tendon assessment may provide a useful diagnostic approach. A method based on pain modification during active ankle dorsiflexion, which alters mechanical tension, may be transferable to the plantar fascia with appropriate modification.

This study is designed as an exploratory diagnostic investigation aimed at evaluating the performance of two clinical assessments: localized tenderness at the medial calcaneal tuberosity and a modified version of the Royal London Hospital Test adapted for PF. The study focuses on assessing diagnostic accuracy in terms of sensitivity, specificity, reproducibility, and predictive values in patients presenting with clinical signs consistent with PF. The modified test has not yet undergone formal validation, and this investigation is intended to provide preliminary evidence regarding its clinical applicability.

In addition, the study explores the role of gastrocnemius tightness within the proposed biomechanical framework by assessing the reproducibility and prevalence of the Silfverskiöld test in the same population.

The study adopts a controlled design with blinded assessment by multiple examiners under standardized conditions. Repeated evaluations within the same day are performed to assess intra- and inter-observer reliability. This methodological approach is intended to ensure robustness in the evaluation of diagnostic performance and to minimize measurement bias.

Overall, the study aims to contribute to the development and validation of simple, clinically applicable diagnostic tools for plantar fasciopathy, with potential implications for improving early diagnosis and optimizing patient management.

Type d'étude

Interventionnel

Inscription (Estimé)

45

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • BO
      • Bologna, BO, Italie, 40136
        • Recrutement
        • IRCCS Istituto Ortopedico Rizzoli
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • PF group:

    • Patients on the waiting list at Clinic I of the Rizzoli Orthopaedic Institute for surgical intervention with a diagnosis of recalcitrant PF lasting at least 12 months
    • Age >18 years
    • MRI of the foot and ankle negative for other local causes of pain included in the differential diagnosis of PF
    • Negative electromyography for tarsal tunnel syndrome
  • Control group:

    • Age >18 years
    • Outpatients followed at Clinic I for conditions unrelated to the foot and ankle, with no clinical history of foot pain or pathology in the preceding 12 months

Exclusion Criteria:

  • PF and control groups:

    • Minor patients
    • Patients with diagnosed rheumatologic diseases currently under pharmacological treatment
    • Patients with diabetes or diabetic neuropathy
    • Pregnant women

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Diagnostique
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: PF group
  • Patients on the waiting list at Clinic I of the Rizzoli Orthopaedic Institute for surgical intervention with a diagnosis of recalcitrant PF lasting at least 12 months
  • Age >18 years
  • MRI of the foot and ankle negative for other local causes of pain included in the differential diagnosis of PF
  • Negative electromyography for tarsal tunnel syndrome
Modified Version of the Royal London Hospital Test (Gastroc Sign) After identifying tenderness at the medial calcaneal tuberosity with the ankle in a neutral or slightly plantarflexed position, participants are asked to actively perform ankle dorsiflexion and plantarflexion with the knee extended. If the tenderness identified in the initial phase decreases or disappears during active dorsiflexion, the test is considered positive.
Palpation is performed with the ankle in a neutral position or slight plantarflexion, gently pressing the medial aspect of the plantar heel region starting from the palpable medial calcaneal tuberosity. Participants are asked to report whether tenderness is present or absent.

The Silfverskiöld test [20] is performed with the patient in the supine position. The examiner uses both hands: one stabilizes and locks the subtalar joint in a neutral position, while the other stabilizes the midtarsal joint and forefoot in supination, ensuring that movement is isolated to the tibiotalar joint.

Tibiotalar dorsiflexion is measured under two conditions:

  • With the knee fully extended
  • With the knee flexed at 90 degrees

Limited dorsiflexion in both positions indicates soleus tightness or a bony block as the cause of stiffness. Reduced dorsiflexion with the knee extended, accompanied by a soft and elastic end-feel, suggests isolated gastrocnemius contracture and is therefore interpreted as a positive Silfverskiöld test.

Comparateur factice: Control group
  • Age >18 years
  • Outpatients followed at Clinic I for conditions unrelated to the foot and ankle, with no clinical history of foot pain or pathology in the preceding 12 months
Modified Version of the Royal London Hospital Test (Gastroc Sign) After identifying tenderness at the medial calcaneal tuberosity with the ankle in a neutral or slightly plantarflexed position, participants are asked to actively perform ankle dorsiflexion and plantarflexion with the knee extended. If the tenderness identified in the initial phase decreases or disappears during active dorsiflexion, the test is considered positive.
Palpation is performed with the ankle in a neutral position or slight plantarflexion, gently pressing the medial aspect of the plantar heel region starting from the palpable medial calcaneal tuberosity. Participants are asked to report whether tenderness is present or absent.

The Silfverskiöld test [20] is performed with the patient in the supine position. The examiner uses both hands: one stabilizes and locks the subtalar joint in a neutral position, while the other stabilizes the midtarsal joint and forefoot in supination, ensuring that movement is isolated to the tibiotalar joint.

Tibiotalar dorsiflexion is measured under two conditions:

  • With the knee fully extended
  • With the knee flexed at 90 degrees

Limited dorsiflexion in both positions indicates soleus tightness or a bony block as the cause of stiffness. Reduced dorsiflexion with the knee extended, accompanied by a soft and elastic end-feel, suggests isolated gastrocnemius contracture and is therefore interpreted as a positive Silfverskiöld test.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
sensitivity
Délai: from the morning to the afternoon of Day 1 - baseline
To evaluate the ability of tenderness at the medial calcaneal tuberosity and the modified Royal London Hospital Test to correctly identify patients with plantar fasciopathy (true positive rate). Sensitivity reflects the proportion of individuals with PF who are accurately detected by the test.
from the morning to the afternoon of Day 1 - baseline
Specificity
Délai: from the morning to the afternoon of Day 1 - baseline
To assess the ability of the same clinical tests to correctly identify individuals without plantar fasciopathy (true negative rate). Specificity represents the proportion of non-PF subjects who are correctly classified as negative.
from the morning to the afternoon of Day 1 - baseline
Reproducibility (Reliability)
Délai: from the morning to the afternoon of Day 1 - baseline
To determine the consistency of the test results when performed by different evaluators (inter-rater reliability) and when repeated by the same evaluator at different time points (intra-rater reliability). This will be quantified using statistical measures such as Cohen's kappa coefficient.
from the morning to the afternoon of Day 1 - baseline
Predictive Value
Délai: from the morning to the afternoon of Day 1 - baseline

To evaluate the clinical usefulness of the tests in practice:

Positive Predictive Value (PPV): the probability that a subject with a positive test result truly has PF.

Negative Predictive Value (NPV): the probability that a subject with a negative test result truly does not have PF.

These measures depend on disease prevalence and will be recalibrated accordingly.

from the morning to the afternoon of Day 1 - baseline

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Reproducibility of the Silfverskiöld Test
Délai: from the morning to the afternoon of Day 1 - baseline
To assess the inter- and intra-rater reliability of the Silfverskiöld test in the study population, determining its consistency as a clinical measure of gastrocnemius tightness.
from the morning to the afternoon of Day 1 - baseline

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Simone Ottavio Zielli, MD, IRCCS Istituto Ortopedico Rizzoli

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 avril 2025

Achèvement primaire (Estimé)

30 août 2026

Achèvement de l'étude (Estimé)

30 septembre 2026

Dates d'inscription aux études

Première soumission

21 avril 2026

Première soumission répondant aux critères de contrôle qualité

28 avril 2026

Première publication (Réel)

5 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 avril 2026

Dernière vérification

1 avril 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 100/2025/Sper/IOR

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner